Evidence map›Paper›PMID 42712824›Full record

ArticleContemporary oncology (Poznan, Poland)2026

Omitting the 5-fluorouracil bolus in metastatic colorectal cancer: impact on survival and toxicity in a retrospective multicentre cohort.

Ahmed Sohaib, Eman H Hebesh, Naglaa Said Elabd, Omnia Korani, Mohamed T Amin, Huda I Abd-Elhafiz, Amira M Badawy, Samar Hosny

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmed SohaibClinical Oncology Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.
Eman H HebeshClinical Oncology Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.
Naglaa Said ElabdTropical Medicine Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.
Omnia KoraniMedical Oncology Department, National Cancer Institute, Cairo, Egypt.
Mohamed T AminRadiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Huda I Abd-ElhafizClinical Pharmacology Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.
Amira M BadawyTropical Medicine Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.
Samar HosnyClinical Oncology Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The clinical value of the 5-fluorouracil (5-FU) bolus in modern multidrug regimens for metastatic colorectal cancer (mCRC) is uncertain, with concerns about added haematologic toxicity. This study assessed the impact of omitting the 5-FU bolus on survival and toxicity in patients receiving mFOLFOX6-based chemotherapy. Material and methods: In this retrospective multicentre cohort, 267 mCRC patients treated between June 2020 and June 2024 at Menoufia University Hospitals and the National Cancer Institute, Cairo University, received either bolus-free nbFOLFOX ( Results: Bolus omission produced a statistically significant but clinically small PFS improvement (mean 10.029 vs. 9.319 months; hazard ratio [HR] 1.532, 95% CI: 1.194-1.967; Conclusions: Omitting the 5-FU bolus does not compromise survival and reduces haematologic toxicity, supporting individualised treatment decisions, particularly in settings of drug shortages or high toxicity risk.

Indexed as

antineoplastic combined chemotherapy protocolscolorectal neoplasmsdrug administration schedulefluorouraciltreatment outcome

Identifiers

PMID42712824
PMCPMC13551323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.